• Skip to main content
BC

biochimica clinica

en_US English
en_US English it_IT Italian
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

CASI CLINICI – Case Reports

Volume:

Biochimica Clinica 2018; 42(2) e15-e17

Pubblicato on-line:

February 27, 2018

DOI:

10.19186/BC_2018.014

Scarica in PDF:
Autenticazione richiesta

La misura delle catene leggere libere indentifica la ricaduta di malattia e orienta per una rivalutazione della tipizzazione dell’amiloide in una paziente con amiloidosi AL

AUTORI

Paolo Milani1, Marco Basset1, Francesca Russo1, Mario Nuvolone1, Francesca Lavatelli1, Tiziana Bosoni2, Laura Pirolini2, Filomena Li Bergolis2, Andrea Foli1, Riccardo Albertini2, Giovanni Palladini1, Giampaolo Merlini1
1Centro per lo Studio e la Cura delle Amiloidosi Sistemiche, Laboratorio Biochimica - Biotecnologie e Diagnostica avanzata, Fondazione IRCCS Policlinico San Matteo, Dipartimento di Medicina Molecolare, Università di Pavia, Pavia
2Servizio di Analisi Chimico Cliniche, Fondazione IRCCS Policlinico San Matteo, Pavia

ABSTRACT

Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis

The detection and quantification of amyloidogenic light-chains (LC) is necessary for diagnosis and evaluation of response in AL amyloidosis. A 69 years old woman was initially diagnosed, in another center, with AL-λ amyloidosis with renal and soft tissue involvement in December 2001. After 4 cycles of therapy with melphalan and dexamethasone serum and urine immunofixation were negative and, after cycle 6, complete remission was confirmed. Free light chain (FLC) ratio was normal until June 2006, when proteinuria increased, and an elevated k-FLC concentration with abnormal k/λ-ratio was documented. We repeated the abdominal fat aspirate for amyloid typing by immune-electron microscopy that revealed k-LC deposits. The diagnosis was AL-k. A relapse was documented and the patient was started on bortezomib and dexamethasone therapy. After 8 cycles, complete remission was obtained. In this case, FLC allowed the identification of the amyloidogenic-LC, enabling the detection of relapse.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967